Clinical Trials Browser

Phase 3 × INDUSTRY × COVID-19 Vaccines × Clear all

NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Phase 3 Completed

165 enrolled 13 charts

COVID-19, Papillomavirus Infections